What this pack is
BELSOMRA is the brand name in this record; suvorexant is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
BELSOMRAGeneric namesuvorexant
How this medicine works
Suvorexant is a dual orexin-receptor antagonist that binds OX1R and OX2R and suppresses wake-promoting orexin signalling. In plain language, it does not ‘switch off’ all brain activity; it reduces one wake-maintaining signal. This mechanism cannot predict individual suitability, strength choice or safe combination with another sleep or sedative medicine.
Read source: United States ↗Current regulatory record · reviewed 2026-08-30More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- BELSOMRA
- Generic name
- suvorexant
- Dosage-form class
- Dosage form and presentation as documented in the linked primary label
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
7 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · Current U.S. DailyMed public label (SPL v21; updated 10 Mar 2025)
Suvorexant 5 mg per tablet; 30-tablet unit-of-use blister carton (3 cards × 10 tablets)
- Product code
- NDC 0006-0005-30
- Form and route
- BELSOMRA suvorexant oral film-coated tablet · oral; exact product-identity field, not an individual tablet count, timing or make-up plan
- Container
- unit-of-use blister carton
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-30; actual marketing, stock and availability are not established.
- suvorexant
- 5 mglabelled amount per tablet; not an individual's tablet count, frequency, timing, make-up, stopping or switching instruction
- Package
- 30 tablets per carton (3 cards × 10 tablets)
- Labelled appearance
- yellow · round, film-coated tablet; unscored · imprint 5Unscored in this labelled presentation
United States label · Current U.S. DailyMed public label (SPL v21; updated 10 Mar 2025)
Suvorexant 10 mg per tablet; 30-tablet unit-of-use blister carton (3 cards × 10 tablets)
- Product code
- NDC 0006-0033-30
- Form and route
- BELSOMRA suvorexant oral film-coated tablet · oral; exact product-identity field, not an individual tablet count, timing or make-up plan
- Container
- unit-of-use blister carton
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-30; actual marketing, stock and availability are not established.
- suvorexant
- 10 mglabelled amount per tablet; not an individual's tablet count, frequency, timing, make-up, stopping or switching instruction
- Package
- 30 tablets per carton (3 cards × 10 tablets)
- Labelled appearance
- green · round, film-coated tablet; unscored · imprint 33Unscored in this labelled presentation
United States label · Current U.S. DailyMed public label (SPL v21; updated 10 Mar 2025)
Suvorexant 15 mg per tablet; 30-tablet unit-of-use blister carton (3 cards × 10 tablets)
- Product code
- NDC 0006-0325-30
- Form and route
- BELSOMRA suvorexant oral film-coated tablet · oral; exact product-identity field, not an individual tablet count, timing or make-up plan
- Container
- unit-of-use blister carton
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-30; actual marketing, stock and availability are not established.
- suvorexant
- 15 mglabelled amount per tablet; not an individual's tablet count, frequency, timing, make-up, stopping or switching instruction
- Package
- 30 tablets per carton (3 cards × 10 tablets)
- Labelled appearance
- white · oval, film-coated tablet; unscored · imprint 325Unscored in this labelled presentation
United States label · Current U.S. DailyMed public label (SPL v21; updated 10 Mar 2025)
Suvorexant 20 mg per tablet; 30-tablet unit-of-use blister carton (3 cards × 10 tablets)
- Product code
- NDC 0006-0335-30
- Form and route
- BELSOMRA suvorexant oral film-coated tablet · oral; exact product-identity field, not an individual tablet count, timing or make-up plan
- Container
- unit-of-use blister carton
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-30; actual marketing, stock and availability are not established.
- suvorexant
- 20 mglabelled amount per tablet; not an individual's tablet count, frequency, timing, make-up, stopping or switching instruction
- Package
- 30 tablets per carton (3 cards × 10 tablets)
- Labelled appearance
- white · round, film-coated tablet; unscored · imprint 335Unscored in this labelled presentation
JP · Current Japanese PMDA electronic label (revised Mar 2026; verified 30 Aug 2026)
Suvorexant 10 mg per tablet; Japanese PMDA product identity
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- PMDA 22800AMX00671000
- Form and route
- BELSOMRA suvorexant oral film-coated tablet (Japan) · oral (exact Japanese product-identity field)
- Container
- pack count not established in this identity card
- Listing review
- Cited public label display reviewed 2026-08-30; actual marketing, stock and availability are not established.
- suvorexant
- 10 mgJapanese labelled amount per tablet; not an individual's tablet count, frequency, age-based regimen or cross-market conversion
- Labelled appearance
- very pale green · round film-coated tablet · imprint 33Unscored in this labelled presentation
JP · Current Japanese PMDA electronic label (revised Mar 2026; verified 30 Aug 2026)
Suvorexant 15 mg per tablet; Japanese PMDA product identity
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- PMDA 22600AMX01302000
- Form and route
- BELSOMRA suvorexant oral film-coated tablet (Japan) · oral (exact Japanese product-identity field)
- Container
- pack count not established in this identity card
- Listing review
- Cited public label display reviewed 2026-08-30; actual marketing, stock and availability are not established.
- suvorexant
- 15 mgJapanese labelled amount per tablet; not an individual's tablet count, frequency, age-based regimen or cross-market conversion
- Labelled appearance
- white · oval film-coated tablet · imprint 325Unscored in this labelled presentation
JP · Current Japanese PMDA electronic label (revised Mar 2026; verified 30 Aug 2026)
Suvorexant 20 mg per tablet; Japanese PMDA product identity
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- PMDA 22600AMX01303000
- Form and route
- BELSOMRA suvorexant oral film-coated tablet (Japan) · oral (exact Japanese product-identity field)
- Container
- pack count not established in this identity card
- Listing review
- Cited public label display reviewed 2026-08-30; actual marketing, stock and availability are not established.
- suvorexant
- 20 mgJapanese labelled amount per tablet; not an individual's tablet count, frequency, age-based regimen or cross-market conversion
- Labelled appearance
- white · round film-coated tablet · imprint 335Unscored in this labelled presentation
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
BELSOMRA label reading: check mg per tablet, next-day alertness, falls and co-medication
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
The 5, 10, 15 and 20 mg figures are labelled suvorexant amounts per tablet, not a personal regimen supplied by this site. Older adults and people also using sleep medicines, sedatives, opioids, alcohol or CYP3A-related medicines particularly need professional review of the full medicine list and actual pack.
- Do not read the pack mg as a tablet count. U.S. and Japanese strengths and label instructions differ; age, interactions and market cannot be converted by this site into an individual tablet count, timing or make-up plan.
- Suvorexant can affect next-day alertness, attention and motor coordination. If morning drowsiness, slowed reactions, unsteady gait or a fall occurs, do not drive, operate hazardous equipment, add another sleep medicine or use alcohol to ‘help sleep’; seek timely professional review.
- Sleep-walking, sleep-driving, eating, making calls or other activities while not fully awake are complex-sleep-behaviour warning signs. If this occurs, secure immediate safety and contact the prescriber; injury, altered awareness or another acute danger requires local emergency support.
- Alcohol, opioids, benzodiazepines, other sleep/sedative medicines, some allergy medicines and other CNS depressants can add drowsiness, slowed reactions, breathing or fall risk. Do not combine, rotate or share them merely because they are all used at night.
- Strong or moderate CYP3A inhibitors and inducers can affect professional management, and the current Japanese label lists several medicines that must not be combined. Bring anti-infectives, cardiovascular medicines, antifungals, antivirals, supplements and the full list for review rather than deciding from one name.
- Narcolepsy is a U.S. label contraindication. Compromised respiratory function, worsening depression or self-harm thoughts, sleep paralysis, hallucination-like experiences and cataplexy-like symptoms also need professional assessment. The site does not diagnose or select treatment from sleep duration, age or symptoms.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-30
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 1
- Japan · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. BELSOMRA suvorexant oral-tablet public label, Medication Guide and four 30-tablet blister-carton panels (SPL v21; updated 10 Mar 2025) ↗Current regulatory record · reviewed 2026-08-30
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- PMDA · Japan · Regulatory product record · 2026-08-30Japan PMDA: current BELSOMRA 10/15/20 mg electronic label (revised Mar 2026) ↗Current regulatory record · reviewed 2026-08-30
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about BELSOMRA (suvorexant). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
BELSOMRA is the brand in this record and suvorexant is the active-ingredient name. Check both with the dosage form (Dosage form and presentation as documented in the linked primary label) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- DailyMed (NLM): current U.S. BELSOMRA suvorexant oral-tablet public label, Medication Guide and four 30-tablet blister-carton panels (SPL v21; updated 10 Mar 2025) ↗Current regulatory record · reviewed 2026-08-30
- Japan PMDA: current BELSOMRA 10/15/20 mg electronic label (revised Mar 2026) ↗Current regulatory record · reviewed 2026-08-30
HOW IT WORKS · NOT A TREATMENT PLAN
How suvorexant works: blocking OX1R and OX2R orexin receptors to reduce wake signalling
- A different mechanism from zolpidem, benzodiazepines or other sleep medicines does not make it better for everyone or permit milligram substitution, alternate-day rotation or combination.
- Originator and generic products can share an active ingredient and regulatory equivalence basis while appearance, excipients and packaging may differ. Substitution requires the current target-market approval and individual prescription, not colour, a shared mechanism or brand name.
- Orexin signalling helps maintain wakefulness, but ‘blocking a wake signal’ cannot establish the cause of insomnia or displace the full label warnings about next-day impairment, falls, breathing, mood or complex sleep behaviours.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): current U.S. BELSOMRA suvorexant oral-tablet public label, Medication Guide and four 30-tablet blister-carton panels (SPL v21; updated 10 Mar 2025) ↗Current regulatory record · reviewed 2026-08-30
- FDA Drugs@FDA: BELSOMRA (suvorexant) NDA 204569 application and label record ↗Current regulatory record · reviewed 2026-08-30
- FDA: BELSOMRA (suvorexant) NDA 204569 original approval letter (13 Aug 2014) ↗reviewed 2026-08-30
- FDA: BELSOMRA suvorexant NDA 204569 cross-discipline review (5/10/15/20 mg) ↗reviewed 2026-08-30
- FDA: BELSOMRA NDA 204569/S-010 supplemental approval letter and lactation-labelling update (2025) ↗reviewed 2026-08-30
- Japan PMDA: current professional product records, electronic label, patient guide and safety-information access for BELSOMRA 10/15/20 mg ↗Current regulatory record · reviewed 2026-08-30
- Japan PMDA: public medicine-information access for BELSOMRA 10/15/20 mg ↗Current regulatory record · reviewed 2026-08-30
- Japan PMDA: current BELSOMRA 10/15/20 mg electronic label (revised Mar 2026) ↗Current regulatory record · reviewed 2026-08-30
- Japan PMDA: patient medicine guide for BELSOMRA 10/15/20 mg ↗Current regulatory record · reviewed 2026-08-30
SOURCE-TRACEABLE ARCHIVE
BELSOMRAsuvorexant
This page includes an exact current U.S. public-label package panel for BELSOMRA, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Initial U.S. NDA 204569 approval
FDA approved BELSOMRA suvorexant 5, 10, 15 and 20 mg oral tablets. Approval history does not establish current local stock or individual suitability.
FDA: BELSOMRA (suvorexant) NDA 204569 original approval letter (13 Aug 2014) ↗Japanese 15 mg and 20 mg products launched
The current PMDA label records approval and launch milestones for the Japanese 15 mg and 20 mg products; this page does not turn them into an age-based tablet count.
Japan PMDA: current professional product records, electronic label, patient guide and safety-information access for BELSOMRA 10/15/20 mg ↗Japanese 10 mg product launched
The current PMDA label records the later 10 mg product; market strength differences are not a basis for self-conversion.
Japan PMDA: current professional product records, electronic label, patient guide and safety-information access for BELSOMRA 10/15/20 mg ↗Current U.S. DailyMed label updated
SPL v21 displays four 30-tablet blister cartons and a Medication Guide, retaining C-IV, next-day impairment and complex-sleep-behaviour boundaries.
DailyMed (NLM): current U.S. BELSOMRA suvorexant oral-tablet public label, Medication Guide and four 30-tablet blister-carton panels (SPL v21; updated 10 Mar 2025) ↗
MARKET SCOPE
Market-record boundary
United States
Current BELSOMRA brand label, Medication Guide, NDA and four exact blister cartons linkedThe page displays official label panels for four 30-tablet cartons. Label presence does not establish local stock, insurance coverage, purchase eligibility or individual suitability.
Japan
Current BELSOMRA 10/15/20 mg product records, electronic label and patient guide linkedThis review retains PMDA product identities and tablet-appearance text but did not obtain an official principal display panel matched one-to-one to a Japanese pack, so no U.S. carton or retail image is substituted.
Mainland China, European Union and other markets
Current regulatory records not yet establishedNo local approval, supply, pack, prescription eligibility or originator/generic relationship is inferred from U.S. or Japanese records.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
Is BELSOMRA just another ordinary sleeping pill?
It is a dual orexin-receptor antagonist with a different mechanism from some other sleep medicines, but it can still cause next-day drowsiness, complex sleep behaviours, falls and interactions. A different mechanism does not mean safer or suitable for everyone.
Which 10, 15 or 20 mg pack should an older adult choose?
Do not choose from age or pack numbers. Market label, full medicine list, liver function, breathing status, fall risk and other medicines can affect professional decisions; have the prescriber review the actual pack and all medicines.
Can I add half a tablet or another sleep medicine when I cannot sleep?
Do not self-add, split, make up or combine tablets. A score or pack mg is not permission to change use; added CNS depression may increase next-day impairment, falls, complex sleep behaviours or breathing risk.
Can alcohol help the medicine work?
Alcohol should not be used as a sleep combination. It can add drowsiness, impaired coordination, memory problems and falls; disclose actual alcohol use for professional review.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.